

# Lead generation of PD-1xVEGFxCTLA-4 trispecific antibody using UniStac platform

Onegene Biotechnology



ONCOLOGY	Lead
Product Type	Antibody
Indication	CRC, G/GEJ adenocarcinoma, Cervical cancer
Target	PD-1, VEGF, CTLA-4
MoA(Mechanism of Action)	PD-1 blockade restores TCR signaling in exhausted T cells to boost effector function and CTLA-4 modulation enhances priming via CD28 co-stimulation. By co-localizing these functions in VEGF-rich tumors, VEGF neutralization drives T-cell infiltration, activation, and shifts the Treg:Teff balance.
Competitiveness	OGB23501(PD-1xVEGFxCTLA-4) is a potential first-in-class/best-in-class trispecific antibody integrating clinically validated anti-PD-1, anti-VEGFA, and anti-CTLA-4 antibody clones. Multi-target engagement and synergistic interactions among anti-PD-1, VEGF and CTLA-4 arms enhance OGB23501's activities in tumor microenvironment (TME), while sparing peripheral CTLA-4-single-positive T cells, potentially leading to significant improvement of its therapeutic window.
Development Stage	Lead
Route of Administration	Q3W, IV administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*